Peter Borsos

[Mark Fermor @fermorm]

Ericsson puts $50M more into US 5G smart factory: Ericsson pumped in an additional $50 million to accelerate production at its US-based 5G smart factory, adding to an initial outlay of $100 million in 2020.

The Swedish vendor announced the investment… https://t.co/JpQxKnJ68D

[Ericsson @ericsson]

Our CEO, @Borje_Ekholm, is urging action to address Europe's lag in #DigitalInfrastructure and competitiveness. 📣 He's raised concerns about the impact of regulation and lengthy antitrust reviews on #investment.

🗣 Read his full interview here:
https://t.co/fGShQuADA3

[Peter Borsos @peteraborsos]

Vonage and Verizon to collaborate on Advanced Network APIs https://t.co/mS4mJAIuPb

[Dagens industri @dagensindustri]

Ericsson-toppen Fredrik Jejdling, chef för största segmentet Nätverk, beskriver jätteordern som första etappen på ett långt lopp. ”Den här typen av affärer är egentligen bara första kilometern på Vasaloppet”, säger han i en exklusiv intervju med Di.
https://t.co/q0kDUVBen9

[Börje Ekholm @Borje_Ekholm]

Building on our company strategy, we’re launching the first commercial operator partnership together with #DeutscheTelekom to offer comms and network APIs to enterprises and developers, all powered by 5G and #Vonage.

Full press release here: https://t.co/DfWUbHcais

#DigitalX

[AlzeCure Pharma AB @AlzeCure]

AlzeCure publishes new disease modifying data with NeuroRestore ACD856 against Alzheimer’s and cognitive disorders

A new scientific article has been published on NeuroRestore ACD856 and preclinical results supporting its disease-modifying effect. NeuroRestore is a Trk-PAM increasing BDNF and NGF signaling to protect and improve learning and memory capabilities.

"The data presented in the article add a substantial amount of information to our growing body of evidence strongly indicating that ACD856 could both have disease modifying and symptomatic effects in Alzheimer’s disease. We are encouraged by the compelling multimodal results with ACD856 demonstrating significant protection against amyloid-beta induced neurotoxicity, enhanced neurite outgrowth and increased levels of BDNF, both in vitro and in vivo in aged animals. Apart from being a stand-alone treatment, the recent findings also enhance the possibilities for ACD856 as a future combination treatment with anti-amyloid antibodies, such as Leqembiä (lecanemab)," said Pontus Forsell, Head of Research and Discovery at AlzeCure Pharma.

“There is major international scientific interest in new therapeutic mechanisms in Alzheimer's and other neurodegenerative diseases. Neurotrophins are a very interesting area with potential for multiple indications, not only Alzheimer's. Depression and Parkinson's are also diseases where this mechanism has scientific support," said Martin Jönsson, CEO of AlzeCure Pharma AB. ”These new results with ACD856 significantly strengthen the commercial potential of the project, which we now prepare for phase II studies.”

Link to the press release:
https://t.co/phpSV8rQTM

The article is available via the following link:
https://t.co/feU1bFQL8R

#alzecure #redeye #alzheimerfonden #avanza #nordnet #edisongroup #seb #swedbank #nordea #aktiespararna #privataaffarer #vatorsecurities #finwire #penser #erikpenserbank #article #NeuroRestore #ACD856

[AlzeCure Pharma AB @AlzeCure]

Positiva data från den kliniska fas IIa-studien med den icke opioida läkemedelskandidaten ACD440, som utvecklas mot perifer neuropatisk smärta.

Läs pressmeddelandet:
https://t.co/QmIYJFW27P

#alzecure #ACD440 #neuropatisksmärta

[Awardit AB (publ) - AWRD @PointmanAwardit]

Awardit levererar sin bästa Q1a någonsin med ett EBITA-resultat på 11,5 mkr (justerat för Connex-förvärvskostnader på 4,4 mkr). I vanlig ordning är kvartalet dock relativt svagt, vilket numera bör vara ett välkänt faktum bland våra aktieägare.

https://t.co/OgSpPT06Mu

[Börje Ekholm @Borje_Ekholm]

We closed Q1 with growth in our enterprise business & cloud software and services

Thanks to #TeamEricsson, executing our strategy paid off, strengthening our leadership in mobile networks & enterprise, and driving our continued cultural transformation.

https://t.co/cfFez7HROR

[Awardit AB (publ) - AWRD @PointmanAwardit]

Pareto har uppdaterat sin analys av Awardit med en ny riktkurs på 200 (180) kr.

https://t.co/sNyx2Sbv2n

[Awardit AB (publ) - AWRD @PointmanAwardit]

Awardit levererar sitt bästa kvartal och år någonsin. Omsättningen under kvartalet uppgick till 205 (229) mkr, en ökning med 33%. EBITA uppgick till 57,6 (57,2), justerat för det covid-stöd på ca 9 mkr som MBXP erhöll 2021 en ökning med 16%.

https://t.co/TKR0SLnMWU

[Awardit AB (publ) - AWRD @PointmanAwardit]

Imorgon fredag kör VD Erik Grohman en sedvanlig investerarpresentation med anledning av Awardits bokslutskommuiké 2022.

https://t.co/2AilF9O3C0

[Börje Ekholm @Borje_Ekholm]

Clear indications of revenue growth in advanced 5G markets.

Read the new Business Review edition of the Ericsson #MobilityReport for insights into 5G service provider revenue growth opportunities.

https://t.co/cxQRsDYbj6

[Awardit AB (publ) - AWRD @PointmanAwardit]

Vi har nu förvärvat det ledande österrikiska lojalitets- och presentkortsföretaget Connex. Detta är ett drömförvärv för oss som vi nu stänger efter en snart två år lång process. Connex matchar utmärkt med vårt tyska dotterbolag Prämie.

https://t.co/t65M8C9Ltx

[AlzeCure Pharma AB @AlzeCure]

AlzeCure has chosen a candidate drug (CD) and started the preclinical development phase with the company's preventive and disease-modifying candidate drug Alzstatin® ACD680. ACD680 is being developed within AlzeCure's Alzstatin platform.........
https://t.co/OrmFn0F1EO

[Peter Borsos @peteraborsos]

Looking forward to join! https://t.co/KbWejsNpQ2

[Toronto Maple Leafs @MapleLeafs]

A warrior. A legend. A Maple Leaf.

We love you, Börje 💙

[Toronto Maple Leafs @MapleLeafs]

Börje 💙

[Awardit AB (publ) - AWRD @PointmanAwardit]

Awardit står starkt i en skakig omvärld, med fortsatt hög organisk tillväxt och förbättrat resultat under Q3. Omsättningen för kvartalet uppgick till 196,0 mkr och EBITA till 20,1 mkr vilket innebär en ökning med 55% resp 33%.

https://t.co/jsz8tUl2JS

[Life Science Sweden @LifeSciSwe]

"Det är fantastiskt positivt. Först och främst är vi jätteglada att det förhoppningsvis kan komma ett preparat för patienterna", säger @AlzeCure ´s vd Martin Jönsson om @bioarcticab ´s fas III-resultat.
https://t.co/X1eblEuZym